# Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry

> **NCT02429505** · — · WITHDRAWN · sponsor: **Knight Therapeutics (USA) Inc**

## Conditions studied

- Leishmaniasis

## Interventions

- **DRUG:** Miltefosine

## Key facts

- **NCT ID:** NCT02429505
- **Lead sponsor:** Knight Therapeutics (USA) Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-07
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was COMPLETED, but no patients were enrolled.
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02429505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02429505, "Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02429505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*